Napo Pharmaceuticals, Inc.

Napo Pharmaceuticals, Inc. is focused on developing and commercializing prescription medicines that enhance the quality of life for patients, particularly those experiencing gastrointestinal distress due to cancer treatments. Founded in 2001 and headquartered in San Francisco, US, Napo Pharmaceuticals, Inc. specializes in pharmaceutical solutions for gastrointestinal issues.

The company has completed 9 deals, with its most recent funding round being Venture Debt in January 2017, raising USD 2. 00 mn from Kingdon Capital Management. The total amount raised by the company amounts to USD 3. 09 mn.

Lisa Conte serves as the CEO. Napo Pharmaceuticals develops innovative prescription medicines designed to improve the quality of life for patients with gastrointestinal distress, especially those undergoing cancer treatment. Its flagship product, Mytesi® (crofelemer), targets treatment-related overactive bowel syndrome, alleviating symptoms like chronic diarrhea and urgency. The medication works by modulating secretory chloride ion channels in the gastrointestinal tract, offering relief to patients with chemotherapy-induced overactive bowel (CIOB).

The company's offerings are sold primarily in the United States, Europe, and select regions in the Middle East and North Africa, with ongoing studies to explore additional indications for rare diseases. Napo Pharmaceuticals generates revenue through the sale of its prescription medication Mytesi®, marketed to healthcare professionals and patients. Sales transactions typically occur through direct-to-consumer channels and partnerships with healthcare providers. The company also emphasizes the role of insurance reimbursements in enhancing accessibility for patients, ensuring a consistent demand for effective treatment options amid the challenges of cancer therapies.

Napo Pharmaceuticals is focusing on expanding its product line and entering new geographic markets, although specific new products and release dates have not been disclosed. The recent Venture Debt funding of USD 2. 00 mn is expected to support these initiatives, furthering their efforts in addressing gastrointestinal issues for patients. The company aims to improve its reach and enhance its offerings for patients suffering from rare diseases, leveraging ongoing studies to inform product development.